Intelligence / Healthtech / New Clinical Trials / Elixiron Immunotherapeutics Inc.
Elixiron Immunotherapeutics Inc.
29 Oct 2026: Trial registered · A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy Volunteers. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 29 Oct 2026
- Title
- A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy Volunteers
- Conditions
- Food Effect in Healthy Volunteers
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Taiwan
- Country
- Taiwan
- Reference
- NCT07903337
- Location
- Taiwan
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Elixiron Immunotherapeutics Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Taiwan
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.